4225 EXECUTIVE SQUARE, LA JOLLA, CA
Reports Full Year 2025 Financial Results and Recent Corporate Updates
To Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Amended material disclosure
Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
Investor Presentation
Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
FY 2025
Q3
Q2
Q1
FY 2024
Q1 amended
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence